Eradication of Pseudomonas aeruginosa in cystic fibrosis

Eur Respir J. 2006 Feb;27(2):438-9. doi: 10.1183/09031936.06.00118805.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Adolescent
  • Anti-Bacterial Agents / administration & dosage*
  • Anti-Bacterial Agents / economics
  • Child
  • Child, Preschool
  • Chronic Disease
  • Cystic Fibrosis / microbiology*
  • Cystic Fibrosis / physiopathology
  • Drug Administration Schedule
  • Drug Costs
  • Drug Resistance, Bacterial
  • Female
  • Humans
  • Lung / physiopathology
  • Male
  • Pseudomonas Infections / drug therapy*
  • Pseudomonas Infections / physiopathology
  • Pseudomonas aeruginosa* / drug effects
  • Pseudomonas aeruginosa* / growth & development
  • Pseudomonas aeruginosa* / isolation & purification
  • Recurrence
  • Respiratory Function Tests
  • Respiratory Tract Infections / drug therapy*
  • Respiratory Tract Infections / microbiology
  • Respiratory Tract Infections / physiopathology
  • Time Factors
  • Treatment Outcome

Substances

  • Anti-Bacterial Agents